Share prices of over $100 can feel daunting, particularly for new investors. But if the value is there, there is no reason not to consider owning fewer shares at a higher price point. Here are five ASX stocks currently priced at over $100 that remain good value.
Image source: Getty Images
CSL Ltd (ASX: CSL)
Australian-based multinational biopharma powerhouse, CSL, has long been an investor darling, known for its reliable returns and healthy dividends.
Twelve months ago, it was trading around the $270 mark. Today, it is sitting at around $180 per share. This swing is likely driven by its revenue downgrades for FY2026 in October, investor concerns about efficiencies as the company looks to restructure, and changes in vaccination behaviour in the US.
For me, this presents a rare opportunity for long-term investors. Despite some recent upheaval, CSL boasts a strong track record of consistent execution, solid earnings, a defensive moat, and a robust growth pipeline – excellent fundamentals that suggest this could be a short-term drop.
Macquarie Group Ltd (ASX: MQG)
Diversified financial services powerhouse, Macquarie Group, has been a solid performer for decades. And this is reflected in its share price performance, which is up 50% over the last five years. But in the last year, it has seen some small declines, down 6%, which may be your opportunity to buy into a quality investment.
Despite prices remaining above the $200 mark, I think upside remains. Macquarie Group offers a solid long-term growth outlook, an attractive dividend profile, and positioning as a market leader in several high-growth industries, including infrastructure and renewable energy.
REA Group Ltd (ASX: REA)
Market leader, REA, is best known to consumers for the popular realestate.com.au property search website. It also offers commercial property search, mortgage broking, and property data services, with revenue streams in Australia and Asia.
Over the last year, it has experienced share price declines of around 35%, from around $270 in early February 2025 to below the $170 mark in early February 2026. The fall has been potentially spurred by several factors, including softer listing volume in 2025, earnings pressure, and investor concern about its high valuation.
That said, it continues to deliver solid results. Analysts can see the upside at current prices, as can the company itself, if recent buybacks are anything to go by.
If you're thinking about making a move on REA, you have an attractive entry point right now.
Cochlear Ltd (ASX: COH)
Implantable hearing device pioneer Cochlear has been leading the way in treating hearing loss for over 40 years. It is widely known for its disciplined approach, characterised by low debt, solid capital management, and consistent cash generation.
In the last 12 months, it too has seen some share price declines, dropping 18%. It's likely these were mostly driven by concerns about high valuations, given that Cochlear continues to deliver impressive results.
And conditions are ripe for this market leader to continue delivering in the long term. It already has robust global operations that generate the majority of its revenue, and that's likely to grow given the world's ageing population. In fact, the World Health Organization predicts that 1 in 10 people globally will require hearing intervention by 2050, up from 1 in 20 today.
For me, Cochlear's recent share price falls are likely short term and provide an excellent opportunity for investors looking to get in on a quality stock with a long-term runway for success.
Pro Medicus Ltd (ASX: PME)
Pro Medicus is a leading provider of radiology and imaging software to hospitals and imaging companies. Its dominant position in the market, capital-light SAAS model, and notable customer retention rates have all made it an investor favourite.
It has experienced significant share price volatility over the last 12 months, dropping from circa $285 a year ago to around $160 right now. This was likely driven by broader softening in the tech sector and overvaluation concerns amongst investors.
Right now, for me, it's a buy. It has exceptional financials, a positive long-term outlook, and is successfully growing its footprint in the lucrative US market. In an industry that is being reshaped by AI, Pro Medicus is poised to continue delivering.
